Category: Active Surveillance

Nearly every man treated for low-risk prostate cancer survives it. That shifts the real question from whether treatment works to what life looks like once it is over. A five-year study followed 866 men and asked them, year after year, about leaking, bowel habits and sexual function. Focal therapy held up best across almost every measure. keep reading

Roughly 60% of men with low-risk prostate cancer start on Active Surveillance, and half walk away within five years, usually because PSA keeps climbing. A new trial asked whether two everyday supplements could steady those numbers. The findings were striking enough to publish, though the researchers stop well short of calling them a recommendation. keep reading

Should every man on active surveillance be monitored the same way? New evidence suggests genetics may hold the answer. Polygenic risk scores could one day refine prostate cancer protocols, helping patients get care that matches their unique risk. keep reading

In a murder mystery, the killer is often hiding in plain sight. The same can happen with prostate cancer. In 10-15% of cases that appear low risk, hidden aggressive disease is waiting for an unexpected twist. A deeper diagnostic workup—mpMRI, genomic analysis, and other tools—can reveal the true nature of the disease before a treatment plan is locked in. keep reading

Focal therapy gives men with localized prostate cancer an appealing option—effective control with fewer side effects. Discover who qualifies for focal treatment, how it compares to radical approaches and Active Surveillance, and why specialized diagnosis is essential. keep reading

Deciding on Active Surveillance for prostate cancer isn’t always straightforward. Adding genomic testing to standard factors like PSA, MRI, and biopsy can reveal hidden risks and help ensure the safest, most personalized treatment path. keep reading

New research asks if healthy lifestyle choices—like diet, supplements, and exercise—can slow the growth of low-risk prostate cancer during active surveillance. While results remain inconclusive, promising signs exist, and minimally invasive focal therapy is emerging as an alternative option. keep reading

Research indicates that regular mpMRI scans and PSA density checks might allow some prostate cancer patients on active surveillance to delay confirmatory biopsy at one year. While the evidence is promising, experts say more study is needed before changing established protocols. keep reading

Recent long-term data reveal that active surveillance can offer high prostate cancer-specific survival when paired with advanced monitoring tools like multiparametric MRI and biomarkers. Experts emphasize the importance of a proactive, technology-driven approach to achieve the best treatment-free survival. keep reading

For years, experts wondered if statins—popular cholesterol-lowering drugs—could shield men from prostate cancer. Now, new evidence suggests statins don't lower prostate cancer risk after all, casting doubt on prior hopes and underscoring the complexity of cancer prevention. keep reading